ABBVIE | Sales 2024 * | 55.19B 50.89B | Sales 2025 * | 58.07B 53.55B | Capitalization | 285B 263B |
|---|---|---|---|---|---|
| Net income 2024 * | 7.74B 7.14B | Net income 2025 * | 10.56B 9.73B | EV / Sales 2024 * | 6.21 x |
| Net Debt 2024 * | 57.92B 53.4B | Net Debt 2025 * | 49.21B 45.37B | EV / Sales 2025 * | 5.75 x |
| P/E ratio 2024 * |
31.3
x | P/E ratio 2025 * |
24.1
x | Employees | - |
| Yield 2024 * |
3.86% | Yield 2025 * |
4.03% | Free-Float | 96.38% |
More Fundamentals
* Assessed data
More news
Latest transcript on AbbVie
More recommendations
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
Richard Gonzalez
CEO | Chief Executive Officer | 70 | 12-12-31 |
Scott Reents
DFI | Director of Finance/CFO | 57 | 12-12-31 |
Robert Michael
PSD | President | 53 | 11-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Roxanne Austin
BRD | Director/Board Member | 63 | 12-12-31 |
Edward Rapp
BRD | Director/Board Member | 66 | 12-12-31 |
| Director/Board Member | 70 | 12-12-31 |
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease.
Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).
Sector
Pharmaceuticals
Related indices
| 1st Jan change | Capi. | |
|---|---|---|
| +40.73% | 734B | |
| +32.83% | 591B | |
| -6.30% | 350B | |
| +15.15% | 315B | |
| +15.00% | 238B | |
| +9.78% | 206B | |
| -5.52% | 204B | |
| +6.17% | 161B | |
| -0.45% | 160B |
